Back to News
Market Impact: 0.15
CNMD Crosses Above Average Analyst Target
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
CONMED shares traded at $46.95, exceeding the average 12-month analyst price target of $46.43 by $0.52, or roughly 1.1%. The move above consensus target may prompt analysts to reassess valuation assumptions or revise price targets, but the article provides no updated ratings, estimates, or company fundamentals.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
CNMD0.20
More News
- ‘Like Kashmir’: How a toxic marble dump yard became a tourist spot in India
- Swiss firms plan to expand China investments as trade deal deepens ties
- Interface earnings missed by $0.01, revenue fell short of estimates
- OmniAb: A Self-Funding Option Book On 433 Partner Programs
- Regeneron: 3 Key Takeaways for Long-Term Investors
- AbbVie: 3 Key Takeaways for Long-Term Investors